Premium
EFFECT OF OCTAPEPTIDE SOMATOSTATIN ANALOGUE (SMS 201‐995) ON PLASMA 7B2 (A NEUROENDOCRINE POLYPEPTIDE) LEVELS IN PATIENTS WITH ACROMEGALY
Author(s) -
NATORI SHOICHI,
IGUCHI HARUO,
OHASHI MASAO,
NAKAO RYUSUKE,
BLOOM STEPHEN R.,
NAWATA HAJIME
Publication year - 1990
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1990.tb03749.x
Subject(s) - acromegaly , medicine , endocrinology , somatostatin , octreotide , basal (medicine) , adenoma , pituitary adenoma , somatotropic cell , pituitary gland , hormone , growth hormone , diabetes mellitus
SUMMARY We studied the sequential changes of plasma levels of immunoreactive ‘7B2’(IR‐7B2), a neuroendocrine polypeptide, after a subcutaneous injection of 50 μg of synthetic octapeptide somatostatin analogue (SMS 201‐995) in seven patients with acromegaly due to GH‐producing pituitary adenoma. Compared to the basal levels, mean plasma IR‐7B2 and GH levels significantly decreased, until 5 and 10 h respectively after the administration of SMS 201‐995. The mean (±SEM) nadir levels of plasma IR‐7B2 and GH were 68.1 ± 101 and 13.1 ±6.9%, respectively, compared to mean plasma levels before treatment (100%). Plasma IR‐7B2 as well as GH levels did not change significantly when saline was administered subcutaneously to three acromegalic patients. In addition, plasma IR‐7B2 levels did not change significantly after the administration of SMS 201.995 in normal subjects or in patients with primary hypothyroidism in whom SMS 201.995 induced a decrease of plasma TSH levels. These results strongly suggest that SMS 201‐995 has an unequivocal suppressive effect on the synthesis and/or the secretion of 7B2 in human somatotroph adenoma cells.